Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial
The International Journal of Cardiovascular Imaging · 18.08.2025 · 41 (9) · 1739-1748
DOI: 10.1007/s10554-025-03472-0 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The International Journal of Cardiovascular Imaging, online erschienen am 18.08.2025. Verfasst von Ryota Kakizaki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Drug-Eluting Stents, Percutaneous Coronary Intervention, Antibodies, Monoclonal, Humanized, Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Bern.
Abstract (Originalsprache)
Higher on-treatment levels of low-density lipoprotein cholesterol in statin-treated patients were reportedly associated with the occurrence of neoatherosclerosis after drug-eluting stent (DES) implantation. We aimed to investigate the impact of alirocumab added to high-intensity statin therapy on neoatherosclerosis formation among patients with acute myocardial infarction (AMI) treated with DES. This was a pre-specified substudy of the PACMAN-AMI trial, a randomized, double-blind trial comparing alirocumab versus placebo added to high-intensity statin therapy in AMI patients. The present study included patients undergoing optical coherence tomography assessment of DES in the culprit lesion at one year. The frequency of neoatherosclerosis, neointimal thickness, and strut malapposition were compared between treatment groups. Among 191 patients (95 with alirocumab and 96 with placebo), neoatherosclerosis was observed in 13 patients (6.8%) at one year. There was no significant difference in the frequency of neoatherosclerosis between treatment groups (alirocumab 4.2% vs. placebo 9.4%, P = 0.25). Among 11 patients with lipid-laden neointima, minimal fibrous cap thickness was greater in the alirocumab group than in the placebo group (217.5 ± 122.5 vs. 87.8 ± 49.1 μm, P = 0.02). Neointimal thickness (136.2 ± 71.1 vs. 151.4 ± 101.4 μm, P = 0.45) and the frequency of malapposed struts (0.94 vs. 0.53%, P = 0.27) were comparable between treatment groups. Among AMI patients treated with DES, there was no significant impact of alirocumab on the frequency of neoatherosclerosis and vessel healing at one year. The observed numerical difference and the finding of more stable neoatheroma in the alirocumab group need further investigation in larger studies with extended follow-up. Graphical abstract Alirocumab was associated with a numerically favourable, though not statistically significant, reduction in neoatherosclerosis at 1 year in AMI culprit lesions treated with newer-generation DES.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
- Department of Cardiovascular Medicine, Shinshu University School of Medicine, Nagano, Japan.
- Division of Cardiology, Department of Medicine II, Kansai Medical University, Osaka, Japan.
- Department of Clinical Research, University of Bern, Bern, Bern, Switzerland.
- Department of Cardiology, Itabashi Chuo Medical Center, Tokyo, Japan.
- Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Förderung
- University of Bern
Zitieren
APA
Kakizaki, R., Ueki, Y., Koskinas, K. C., Shibutani, H., Losdat, S., Biccirè, F. G., Otsuka, T., Häner, J. D., Lønborg, J., Kaiser, C., Iglesias, J. F., Ondracek, A. S., Spirk, D., Siontis, G. C. M., Daemen, J., Engstrøm, T., Lang, I. M., & Räber, L. (2025). Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial. The International Journal of Cardiovascular Imaging, 41(9), 1739-1748. https://doi.org/10.1007/s10554-025-03472-0
Vancouver
Kakizaki R, Ueki Y, Koskinas KC, Shibutani H, Losdat S, Biccirè FG, et al. Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial. The International Journal of Cardiovascular Imaging. 2025;41(9):1739-1748. doi:10.1007/s10554-025-03472-0
BibTeX
@article{Kakizaki2025,
author = {Kakizaki, Ryota and Ueki, Yasushi and Koskinas, Konstantinos C and Shibutani, Hiroki and Losdat, Sylvain and Biccirè, Flavio G and Otsuka, Tatsuhiko and Häner, Jonas D and Lønborg, Jacob and Kaiser, Christoph and Iglesias, Juan F and Ondracek, Anna S and Spirk, David and Siontis, George C M and Daemen, Joost and Engstrøm, Thomas and Lang, Irene M and Räber, Lorenz},
title = {Impact of alirocumab on neoatherosclerosis formation and vessel healing after drug-eluting stent implantation in patients with acute myocardial infarction: a substudy of the PACMAN-AMI trial},
journal = {The International Journal of Cardiovascular Imaging},
year = {2025},
volume = {41},
number = {9},
pages = {1739--1748},
doi = {10.1007/s10554-025-03472-0}
}
EUVIMED